Literature DB >> 22183930

Advanced magnetic resonance imaging of neuromyelitis optica: a multiparametric approach.

A Pichiecchio1, E Tavazzi, G Poloni, M Ponzio, F Palesi, M Pasin, L Piccolo, D Tosello, A Romani, R Bergamaschi, G Piccolo, S Bastianello.   

Abstract

BACKGROUND: Several authors have used advanced magnetic resonance imaging (MRI) techniques to investigate whether patients with neuromyelitis optica (NMO) have occult damage in normal-appearing brain tissue, similarly to multiple sclerosis (MS). To date, the literature contains no data derived from the combined use of several advanced MRI techniques in the same NMO subjects.
OBJECTIVE: We set out to determine whether occult damage could be detected in the normal-appearing brain tissue of a small group of patients with NMO using a multiparametric MRI approach.
METHODS: Eight female patients affected by NMO (age range 44-58 years) and seven sex- and age-matched healthy controls were included. The techniques used on a 1.5 T MRI imaging scanner were magnetization transfer imaging, diffusion tensor imaging, tract-based spatial statistics, spectroscopy and voxel-based morphometry in order to analyse normal-appearing white matter and normal-appearing grey matter.
RESULTS: Structural and metabolic parameters showed no abnormalities in normal-appearing white matter of patients with NMO. Conversely, tract-based spatial statistics demonstrated a selective alteration of the optic pathways and the lateral geniculate nuclei. Diffusion tensor imaging values in the normal-appearing grey matter were found to be significantly different in the patients with NMO versus the healthy controls. Moreover, voxel-based morphometry analysis demonstrated a significant density and volume reduction of the sensorimotor cortex and the visual cortex.
CONCLUSIONS: Our data disclosed occult structural damage in the brain of patients with NMO, predominantly involving regions connected with motor and visual systems. This damage seems to be the direct consequence of transsynaptic degeneration triggered by lesions of the optic nerve and spine.

Entities:  

Mesh:

Year:  2011        PMID: 22183930     DOI: 10.1177/1352458511431072

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  22 in total

1.  Longitudinal ultra-high field MRI of brain lesions in neuromyelitis optica spectrum disorders.

Authors:  Sanjeev Chawla; Yulin Ge; Jens Wuerfel; Shadi Asadollahi; Suyash Mohan; Friedemann Paul; Tim Sinnecker; Ilya Kister
Journal:  Mult Scler Relat Disord       Date:  2020-03-25       Impact factor: 4.339

Review 2.  The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Authors:  Ruth Geraldes; Olga Ciccarelli; Frederik Barkhof; Nicola De Stefano; Christian Enzinger; Massimo Filippi; Monika Hofer; Friedemann Paul; Paolo Preziosa; Alex Rovira; Gabriele C DeLuca; Ludwig Kappos; Tarek Yousry; Franz Fazekas; Jette Frederiksen; Claudio Gasperini; Jaume Sastre-Garriga; Nikos Evangelou; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2018-03-09       Impact factor: 42.937

3.  Altered neurovascular coupling in neuromyelitis optica.

Authors:  Xi Guo; Jiajia Zhu; Ningnannan Zhang; Linjie Zhang; Yuan Qi; Huanhuan Cai; Xue Zhang; Jie Sun; Qiuhui Wang; Li Yang; Fu-Dong Shi; Chunshui Yu
Journal:  Hum Brain Mapp       Date:  2018-10-13       Impact factor: 5.038

4.  Neuromyelitis optica: atypical clinical and neuroradiological presentation.

Authors:  Alessandra Splendiani; Silvia Mariani; Monica Anselmi; Alessia Catalucci; Ernesto Di Cesare; Massimo Gallucci
Journal:  Neuroradiol J       Date:  2015-02

5.  Brain parenchymal damage in neuromyelitis optica spectrum disorder - A multimodal MRI study.

Authors:  F Pache; H Zimmermann; C Finke; A Lacheta; S Papazoglou; J Kuchling; J Wuerfel; B Hamm; K Ruprecht; F Paul; A U Brandt; M Scheel
Journal:  Eur Radiol       Date:  2016-03-24       Impact factor: 5.315

6.  Neuroradiological evaluation of demyelinating disease.

Authors:  Jan-Mendelt Tillema; Istvan Pirko
Journal:  Ther Adv Neurol Disord       Date:  2013-07       Impact factor: 6.570

Review 7.  MRI characteristics of neuromyelitis optica spectrum disorder: an international update.

Authors:  Ho Jin Kim; Friedemann Paul; Marco A Lana-Peixoto; Silvia Tenembaum; Nasrin Asgari; Jacqueline Palace; Eric C Klawiter; Douglas K Sato; Jérôme de Seze; Jens Wuerfel; Brenda L Banwell; Pablo Villoslada; Albert Saiz; Kazuo Fujihara; Su-Hyun Kim
Journal:  Neurology       Date:  2015-02-18       Impact factor: 9.910

Review 8.  Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.

Authors:  Stephane Kremer; Felix Renard; Sophie Achard; Marco A Lana-Peixoto; Jacqueline Palace; Nasrin Asgari; Eric C Klawiter; Silvia N Tenembaum; Brenda Banwell; Benjamin M Greenberg; Jeffrey L Bennett; Michael Levy; Pablo Villoslada; Albert Saiz; Kazuo Fujihara; Koon Ho Chan; Sven Schippling; Friedemann Paul; Ho Jin Kim; Jerome de Seze; Jens T Wuerfel; Philippe Cabre; Romain Marignier; Thomas Tedder; Danielle van Pelt; Simon Broadley; Tanuja Chitnis; Dean Wingerchuk; Lekha Pandit; Maria Isabel Leite; Metha Apiwattanakul; Ingo Kleiter; Naraporn Prayoonwiwat; May Han; Kerstin Hellwig; Katja van Herle; Gareth John; D Craig Hooper; Ichiro Nakashima; Douglas Sato; Michael R Yeaman; Emmanuelle Waubant; Scott Zamvil; Olaf Stüve; Orhan Aktas; Terry J Smith; Anu Jacob; Kevin O'Connor
Journal:  JAMA Neurol       Date:  2015-07       Impact factor: 18.302

Review 9.  Conventional and advanced imaging in neuromyelitis optica.

Authors:  Y Barnett; I J Sutton; M Ghadiri; L Masters; R Zivadinov; M H Barnett
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-13       Impact factor: 3.825

Review 10.  Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system.

Authors:  Joseph Kuchling; Alexander U Brandt; Friedemann Paul; Michael Scheel
Journal:  EPMA J       Date:  2017-07-25       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.